Senator Collins Announces $25 Million Initiative to Fight Lyme Disease
Last year, Senator Collins authored a new law that provides $150 million over five years to fight tick-borne illnesses.
Washington, D.C.— U.S. Senator Susan Collins, a member of the Health Committee, announced the launch of LymeX, a new $25 million effort to fight tick-borne diseases. LymeX is the largest public-private partnership to combat Lyme disease in history and will provide awards to improve data about tick-borne diseases; raise awareness; and accelerate the discovery of diagnostic tools, testing, and implementation. Senator Collins, the author of the Kay Hagan Tick Act that became law last year, received a call today from Department of Health and Human Services (HHS) Deputy Secretary Eric Hargan, who shared this positive development.
LymeX is being led by HHS and the Steven & Alexandra Cohen Foundation and will be housed within the HHS Office of the Assistant Secretary for Health, the coordinating agency developing the National Strategy to fight tick-borne diseases that was required by Senator Collins’ Tick Act. LymeX augments the Tick Act law and reinforces the federal focus on this priority.
“This partnership is an exciting and promising development in our fight against tick-borne illnesses such as Lyme disease that affect hundreds of thousands of Americans every year. As the largest public-private partnership to combat Lyme disease in history, this initiative builds on the bipartisan TICK Act I authored and demonstrates that the federal government is focused on eradicating this public health threat,” said Senator Collins. “I remain committed to slowing the spread of these devastating diseases, and I will continue my efforts to protect Mainers’ health.”
Specifically, LymeX will advance tick-borne disease innovation by incentivizing the development of next-generation diagnostics through a series of multi-million-dollar grand prize challenges. The first LymeX diagnostics prize will launch in 2021. These prizes will be open to U.S. universities, non-profit organizations, private-sector companies, and domestic organizations to improve diagnostics at all stages of Lyme disease.
The initiative will also engage stakeholders to facilitate patient-centered innovations to address tick-borne diseases and increase education to raise awareness about risk and prevention.
The incidence of Lyme and other tick-borne diseases has exploded over the past 15 years. In 2003, Lyme disease infected around 30,000 Americans. The latest estimates show there are nearly half a million Americans suffering from Lyme. In Maine, there were a record 2,167 newly reported cases of Lyme disease last year, nearly triple the number of cases in 2010. Other tick-borne diseases are also on the rise – in Maine, for example, Anaplasmosis and Babesiosis have increased several-fold in this same period.
LymeX will complement the three-pronged approach created by Senator Collins’ Tick Act law, which:
- Requires HHS to develop a National Strategy. This will help expand research, improve testing and treatment, and coordinate common efforts across federal agencies including with DOD, USDA, EPA, the VA, and the Departments of Interior and Homeland Security
- Reauthorizes Regional Centers of Excellence in Vector-Borne Disease for five years at $10 million per year. These Centers have led the scientific response against tick-borne diseases, which now make up 75 percent of vector-borne diseases in the U.S.
- Authorizes CDC Grants at $20 million per year for State Health Departments to improve data collection and analysis, support early detection and diagnosis, improve treatment, and raise awareness. These awards will help states build a public health infrastructure for Lyme and other tick and vector-borne diseases and amplify their initiatives through public-private partnerships.
Involving the HHS will almost certainly doom this project. We should learn from history. The anti-patient bias is clear and has remained unchanged: https://madisonarealymesupportgroup.com/2018/02/11/anti-patient-bias-embedded-in-tickborne-disease-working-group-and-its-subcommittees/
Remarks made after the vote made it clear that the abstainers felt they had defeated the measure, because “yes” votes didn’t comprise a majority of panel members. But, oops, guess what? Abstentions don’t count one way or the other. So, the recommendation passed, 5-3.
As that reality sank in, pandemonium broke out. Panelist Scott Commins stoutly announced that he wanted to change his abstaining vote to “no.” He was told that Robert’s Rules of Order don’t allow you to change your vote after the fact.
Things then got very bizarre very fast, with many people talking at once. Some wanted to vote on the original question again. Others didn’t. Some wanted to re-open discussion, others didn’t. It was confusing to the listener at home.
However, the five abstainers sure gave the impression they had been trying to game the system—to gain a “no” vote without having to publicly own up to it. When that ploy didn’t work, they scrambled to recoup their original objective— to deep-six the proposal regarding persistent Lyme disease.
It is truly time for a CDC/NIH/IDSA/HHS walkout movement. Our public health ‘authorities’ have vested interests which interfere with doing what is right for patients. We’ve tried working with them for over 40 years. How many times are you going to get behind a horse that kicks you?
https://madisonarealymesupportgroup.com/2020/09/01/it-is-time-to-reboot-public-health-time-for-a-cdc-niaid-fda-walk-away-movement/ Although Weiler is discussing how ‘authorities’ have handled COVID, the exact same things could be said about how they’ve handled Lyme/MSIDS.
Public ‘authorities’ should not be allowed to own patents on things that interfere with their ability to make public health decisions.
For more: ConflictReport